Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-inducedapoptosis in prostate cancer cells

International Journal of Oncology

Volumn 33, Issue 2, 2008, Pages 381-388

  Festuccia, Claudio ^a,c   Gravina, Giovanni Luca ^a   D'Alessandro, Anna Maria ^a   Millimaggi, Danilo ^a   Di Rocco, Cristiana ^b   Dolo, Vincenza ^a   Ricevuto, Enrico ^a   Vicentini, Carlo ^a   Bologna, Mauro ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c Department of Experimental Medicine ^*  (Italy)

Author keywords

5 aza deoxycytidine; Decitabine; DNA methyltransferase; Epigenetics; Prostate cancer; TRAIL

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CASPASE 8; CASPASE 8 INHIBITOR; CASPASE 8 INHIBITORY PROTEIN PEA 15; CASPASE 8 INHIBITORY PROTEIN PED; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; PROTEIN KINASE B; PROTEIN P53; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR AGONIST;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; GENE ACTIVATION; HOST RESISTANCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLOTTING, WESTERN; CASPASE 8; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 48749129901     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000019     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Salesi N, Carlini P, Ruggeri EM, et al: Prostate cancer: the role of hormonal therapy. J Exp Clin Cancer Res 24: 175-180, 2005.
3. Arnold JT and Isaacs JT: Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 9: 61-73, 2002.
4. Ai L, Kim WJ, Kim TY, Fields CR, Massoll NA, Robertson KD and Brown KD: Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res 66: 7899-7909, 2006.
5. Lodygin D, Epanchintsev A, Menssen A, Diebold J and Hermeking H: Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 65: 4218-4227, 2005.
6. Cho NY, Kim BH, Choi M, et al: Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 211: 269-277, 2007.
7. Karpf AR, Moore BC, Ririe TO and Jones DA: Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine. Mol Pharmacol 59: 751-757, 2001.
8. Pulukuri SM and Rao JS: Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2′-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int J Oncol 26: 863-871, 2005.
9. Momparler RL, Bouchard J and Samson J: Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2′-deoxycytidine. Leuk Res 9: 1361-1366, 1985.
10. McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ and Day ML: Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 66: 385-392, 2006.
11. Shresta S, Pham CT, Thomas TA Graubert and Ley TJ: How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 98: 581-587, 1998.
12. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
13. Ng CP and Bonavida B: A new challenge to immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv Cancer Res 85: 145-174, 2002.
14. Yamana K, Bilim V, Hara N, et al: Prognostic impact of FAS/CD95/ APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 93: 544-551, 2005.
15. Irmler M, Thome M, Hahne MP, et al: Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195, 1997.
16. Roth W, Isenmann S, Nakamura M, et al: Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 61: 2759-2765, 2001.
17. Kim S, Kang J, Qiao J, Thomas RP, Evers BM and Chung DH: Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J Pediatr Surg 39: 516-521, 2004.
18. Larribere L, Khaled M, Tartare-Deckert S, et al: PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ 11: 1084-1091, 2004.
19. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Syrbu SI and Cohen MB: TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP. Cancer Biol Ther 1: 631-637, 2002.
20. Harada K, Toyooka S, Shivapurkar N, et al: Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 62: 5897-5901, 2002.
21. Eramo A, Pallini R, Lotti F, et al: Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res 65: 11469-11477, 2005.
22. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N and Brodeur GM: Resistance to tumor necrosis factor-related apoptosis-inducing ligand TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61: 1314-1319, 2001.
23. Thakkar H, Chen X, Tyan F, et al: Pro-survival function of Akt/ protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. J Biol Chem 276: 38361-38369, 2001.
24. Chen X, Thakkar H, Tyan F, et al: Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073-6083, 2001.
25. + T lymphocytes express APO2 ligand APO2L/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity. J Immunol 169: 809-817, 2002.
26. Gollob JA, Sciambi CJ, Peterson BL, et al: Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 12: 4619-4627, 2006.
27. Pohlmann P, Di Leone LP, Cancella AI, et al: Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 25: 496-501, 2002.
28. Schrump DS, Fischette MR, Nguyen DM, et al: Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12: 5777-5785, 2006.
29. Tolcher AW, Mita M, Meropol NJ, et al: Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25: 1390-1395, 2007.